Evidence map›Paper›PMID 30246937›Full record

ArticleBJU international2019

Characterising potential bone scan overuse amongst men treated with radical prostatectomy.

Peter S Kirk, Tudor Borza, Megan E V Caram, Dean A Shumway, Danil V Makarov, Jennifer A Burns, Jeremy B Shelton, John T Leppert, Christina Chapman, Michael Chang and 2 more

Registry-linked trialAbstract read
In one paragraph

Article in BJU international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03445559 (A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03445559 naactive not recruitingnot on this map

A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2018 to 2027Enrolled58ConditionsProstate CancerArmsClinical Order Check, Academic Detailing, Audit and Feedback
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Prostate Cancer Surveillance After Radiation Therapy in a National Delivery System.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peter S KirkDow Division of Health Services Research, Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA.ORCID 0000-0001-7638-8089
Tudor BorzaDow Division of Health Services Research, Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA.
Megan E V CaramDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Dean A ShumwayDepartment of Radiation Oncology, University of Michigan Health System, Ann Arbor, MI, USA.
Danil V MakarovDepartments of Urology and Population Health, NYU Langone Medical Center, New York, NY, USA.
Jennifer A BurnsVA Health Services Research and Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Jeremy B SheltonVA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
John T LeppertDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
Christina ChapmanVA Health Services Research and Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Michael ChangHunter Holmes McGuire VA Medical Center, Richmond, VA, USA.
Brent K HollenbeckDow Division of Health Services Research, Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA.
Ted A SkolarusDow Division of Health Services Research, Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA.ORCID 0000-0002-5859-8151

Funding

Research Education CoreP30AG024824 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Neil Alexander · 2004 to 2026
$29.2M
De-implementation of low value castration for men with prostate cancerR37CA222885 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SAINI, SAMEER DEV, SKOLARUS, TED ALBERT · 2018 to 2023
$3.6M
Advanced Training in Urologic OncologyT32CA180984 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu, VAHAKN B SHAHINIAN · 2014 to 2026
$3.4M
Michigan Institute for Clinical and Health Research (MCHR)TL1TR000435 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$1.8M
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spendingR01HS025707 · AHRQ · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLLENBECK, BRENT K., SHAHINIAN, VAHAKN B · 2017 to 2021
$1.7M
Improving the prostate cancer survivorship care of veteransIK2HX001162 · VA · VETERANS HEALTH ADMINISTRATION · PI SKOLARUS, TED ALBERT · 2015 to 2018
–
AHRQ HHS R01 HS025707HSRD VA IK2 HX001162NCATS NIH HHS TL1 TR000435NCI NIH HHS R37 CA222885NCI NIH HHS T32 CA180984NIA NIH HHS P30 AG024824
6 · The paper itself

Abstract

objectivesTo characterise bone scan use, and potential overuse, after radical prostatectomy (RP) using data from a large, national integrated delivery system. Overuse of imaging is well documented in the setting of newly diagnosed prostate cancer, but whether overuse persists after RP remains unknown. PATIENTS AND

methodsWe identified 12 269 patients with prostate cancer treated with RP between 2005 and 2008 using the Veterans Administration Central Cancer Registry. We used administrative and laboratory data to examine rates of bone scan use, including preceding prostate-specific antigen (PSA) levels, and receipt of adjuvant or salvage therapy. We then performed multivariable logistic regression to identify factors associated with post-RP bone scan use.

resultsAt a median follow-up of 6.8 years, one in five men (22%) underwent a post-RP bone scan at a median PSA level of 0.2 ng/mL. Half of bone scans (48%) were obtained in men who did not receive further treatment with androgen-deprivation or radiation therapy. After adjustment, post-RP bone scan was associated with a prior bone scan (adjusted odds ratio [aOR] 1.55, 95% confidence interval [CI] 1.32-1.84), positive surgical margin (aOR 1.68, 95% CI 1.40-2.01), preoperative PSA level (aOR 1.02, 95% CI 1.01-1.03), as well as Hispanic ethnicity, Black race, and increasing D'Amico risk category, but not with age or comorbidity.

conclusionWe found a substantial rate of bone scan utilisation after RP. The majority were performed for PSA levels of <1 ng/mL where the likelihood of a positive test is low. More judicious use of imaging appears warranted in the post-RP setting.

Indexed as

ProstatectomyAgedAndrogen AntagonistsBone NeoplasmsCombined Modality TherapyHumansMaleMargins of ExcisionMiddle AgedProcedures and Techniques UtilizationProstate-Specific AntigenProstatic NeoplasmsSalvage TherapyTomography, X-Ray ComputedAndrogen AntagonistsProstate-Specific Antigendiagnostic imagingneoplasm metastasisprostatectomyprostatic neoplasmsradionuclide imaging

Identifiers

PMID30246937
PMCPMC6431565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.